Abstract
In recent years, the ongoing need for novel pharmaceuticals to be introduced in human medicine has substantially benefited from the widespread research activity on the role of bioactive microbial compounds involved in the regulation of interactions with other organisms. A good example is represented by 3-O-methylfunicone, a benzo-γ-pyrone metabolite at first characterized on account of the antifungal aptitude of the producing strain, which has later become more valuable for its antiproliferative and pro-apoptotic properties resulting in a series of studies on human tumor cell lines. An overview of aspects concerning molecular structure, sources, and biological properties of this compound is offered in the present paper.
Keywords: Antitumor drugs, benzo-γ-pyrones, bioactivity, funicone compounds, Penicillium pinophilum, Talaromyces pinophilus.
Mini-Reviews in Medicinal Chemistry
Title:Structural and Bioactive Properties of 3-O-Methylfunicone
Volume: 14 Issue: 13
Author(s): Rosario Nicoletti, Monica Scognamiglio and Antonio Fiorentino
Affiliation:
Keywords: Antitumor drugs, benzo-γ-pyrones, bioactivity, funicone compounds, Penicillium pinophilum, Talaromyces pinophilus.
Abstract: In recent years, the ongoing need for novel pharmaceuticals to be introduced in human medicine has substantially benefited from the widespread research activity on the role of bioactive microbial compounds involved in the regulation of interactions with other organisms. A good example is represented by 3-O-methylfunicone, a benzo-γ-pyrone metabolite at first characterized on account of the antifungal aptitude of the producing strain, which has later become more valuable for its antiproliferative and pro-apoptotic properties resulting in a series of studies on human tumor cell lines. An overview of aspects concerning molecular structure, sources, and biological properties of this compound is offered in the present paper.
Export Options
About this article
Cite this article as:
Nicoletti Rosario, Scognamiglio Monica and Fiorentino Antonio, Structural and Bioactive Properties of 3-O-Methylfunicone, Mini-Reviews in Medicinal Chemistry 2014; 14 (13) . https://dx.doi.org/10.2174/1389557514666141127142838
DOI https://dx.doi.org/10.2174/1389557514666141127142838 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets subject Index To Volume 1
Current Molecular Medicine From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design The Management of Thymoma - A Review of the Status Quo with Practical Treatment Recommendations
Current Respiratory Medicine Reviews Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism Meet Our Editorial Board Member:
Recent Patents on Regenerative Medicine The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Biopolymer-based Scaffolds for Tissue Engineering Applications
Current Drug Targets Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Epigenetics of Virus-Induced Tumors: Perspectives for Therapeutic Targeting
Current Pharmaceutical Design Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery